Voyager Therapeutics
VYGR
69 hedge funds and large institutions have $143M invested in Voyager Therapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 15 closing their positions.
917% more call options, than puts
Call options by funds: $4.47M | Put options by funds: $440K
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
12% more capital invested
Capital invested by funds: $127M → $143M (+$15.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.16% less ownership
Funds ownership: 62.61% → 62.45% (-0.16%)
12% less funds holding
Funds holding: 78 → 69 (-9)
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.33M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.85M |
| 3 |
Morgan Stanley
New York
|
+$1.41M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.21M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$6.16M |
| 2 |
Millennium Management
New York
|
-$3.24M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$827K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$596K |
| 5 |
E
Ergoteles
New York
|
-$344K |
VYGR Hedge Fund Activity: Q3 2022 in Review
69 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q3 2022, worth a combined $143M — up 12% from $127M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of VYGR and 6 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 23 added.
The largest buyer was Armistice Capital, adding an estimated $5.33M. The largest seller was TRV GP III, cutting an estimated $6.16M.
- 69 institutional investors held Voyager Therapeutics (VYGR) as of Q3 2022, down from 78 in Q2 2022.
- Funds reported $143M of Voyager Therapeutics stock for Q3 2022, up 12% quarter-over-quarter.
- 6 funds opened new Voyager Therapeutics positions in Q3 2022 and 15 closed out, a net change of -9 holders.
- The largest Voyager Therapeutics buyer in Q3 2022 was Armistice Capital, an estimated $5.33M added.
- The largest Voyager Therapeutics seller in Q3 2022 was TRV GP III, an estimated $6.16M sold.
Based on aggregated 13F filings for Q3 2022.